Clin Osteol 2008; 13(2): 40-48

Glucocorticoid-induced osteoporosisReview articles

S. Skácelová

Glucocorticoid excess in the organism, either of endogenous (Cushing's syndrome) or exogenous iatrogenic origin, has an adverse im­ pact on both qualitative and quantitative properties of bone tissue, leading to its increased fragility. Glucocorticoid-induced osteopo­ rosis (GIOP) is one of the most common complications of systemic corticotherapy. In glucocorticoid users, the age-and sex-adjusted bone mineral density (BMD) values are lower than expected. Lower BMD correlates with the cumulative dose of corticoids. There is a predilection for the involvement of trabecular bone of the vertebral body. Corticodependent patients have higher risk of fractures of any localization, in particular vertebral compression fractures. The risk increases with the daily doses of glucocorticoids. Current or previous corticoid therapy is a predictor of fracture risk, independent of BMD values. Supraphysiological doses of glucocorticoids have a negative impact on bone tissue metabolism at many levels. They directly influence cells participating in the bone remodelling cycle and cause imbalance between bone resorption and formation. The main pathogenic mechanism is a steady decrease in new bone formation. The exception is the period immediately after glucocorticoid therapy is started, characterized by accelerated bone resorp­ tion. Glucocorticoids inhibit the differentiation of new osteoblasts, decrease the synthesis of organic bone matrix components by mature osteoblasts and stimulate osteoblast and osteocyte apoptosis. At the subcellular level, they significantly interfere with the Wnt/beta-catenin signalling pathway. Through RANKL (receptor activator of nuclear factor kappa B ligand), they promote osteoclast differentiation and maturation. Also important is their impact on the regulatory system ofbone microenvironment growth factors (IGF I, II, IGFBP). The use of glucocorticoids is related to negative calcium balance, hypogonadism and muscular atrophy. The role of pa­ rathormone in corticoid-induced bone loss is yet to be elucidated. The epidemiological and pathophysiological patterns of GIOP also influence the principles of its prevention and therapy.

Keywords: glucocorticoids, glucocorticoid-induced osteoporosis

Published: December 11, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skácelová S. Glucocorticoid-induced osteoporosis. Osteologický bulletin. 2008;13(2):40-48.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. van Staa TP, Leufkens HGM, Abenhaim L et al. Use of oral corticosteroids in United Kingdom. Q J Med 2000;93:105-111. Go to original source...
    2. van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-in­ duced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-787. Go to original source...
    3. Natsui K, Tanaka K, Suda M et al. High-dose glucocorticoid treatment induces rapid loss of tr 2006;17:105-108. Go to original source...
    4. Lann RF, van Riel PL, van de Putte LB, van Erning LJ et al. Low-dose predniso­ ne induces rapid reversible axial bone loss in patients with rheumatoid arthrit A randomized, controlled study. Ann Intern Med 1993;119:963-8. Go to original source...
    5. Dalle Carbonare L, Arlott ME, Chavassieux PM et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmeno­ pausal osteoporosis. J Bone Miner Res 2001;16:97-103. Go to original source...
    6. Dalle Carbonare L, Bertoldo F, Valentini MT et al. Histomorphometric a of glucocorticoid-induced osteoporosis: a review. Micron 2005;36:645-652. Go to original source...
    7. Chappard D, Legrand E, Basle MF et al. Altered Trabecular Architecture Ind by corticosteroids: A bone histomorphometric study. J Bone Miner Res 1996;11: 676-685. Go to original source...
    8. Vedi S, Elkin SL, Compston JE. A histomorphometric study of cortical bone of the il 79-83.
    9. van Staa TP, Leufkens HGM et al. Use of oral corticosteroids and risk of frac res. J Bone Miner Res 2000;15:993-1000. Go to original source...
    10. van Staa TP, Leufkens HGM, Cooper C.The epidemiology of corticosteroid-indu­ ced osteoporosis:a meta-analysis. Osteoporos Int 2002;13:777-787. Go to original source...
    11. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid u increase risk of fracture. Osteoporos Int 2004;15:323-328. Go to original source...
    12. Angeli A, Giuseppe G, Dovio A et al. High prevalence of asymptomatic ver fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study. Bone 2006; 39:253-259. Go to original source...
    13. van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other predic­ tors of vertebral fracture tis Rheum 2003;48:324-3229. Go to original source...
    14. Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid and fracture risk. J Bone Miner Res 2004;19:893-899. Go to original source...
    15. Cooper MS. Sensitivity of bone to glucocorticoids.Clinical Science 2004;107: 111-123. Go to original source...
    16. Valcourt U, Moustakas A BMP signaling in osteogenesis bone remodeling and repair. Eur J Trauma 2005;31:464-179. Go to original source...
    17. Canalis E, Mazziottti G, Giustina A at al. Glucocorticoid-induced osteoporos pathophysiology and therapy. Osteoporos Int 2007;18:1319-1328. Go to original source...
    18. Akune T, Ohba S, Kamekura S et al. PPARy insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004; 113:846-855. Go to original source...
    19. Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev Endocr Metab Di­ sord 2006;7:41-49. Go to original source...
    20. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid supp­ resses the canonical Wnt signal in cultured human osteoblasts. Biochemical and Biophysical Research Communications 2005;329:177-181. Go to original source...
    21. Hernández MV, Guan abens N, Alvarez L et al. Immunocytochemical evidence on the effects of glucocorticoids on type I cells. Calcif Tissue Int 2004;74:284-293. Go to original source...
    22. Seeman E. 17:1443-1448. Go to original source...
    23. O'Brien CHA. Jia D, Plotkin LI et al. Glucocorticoids act directly on osteobl and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145:1835-1841. Go to original source...
    24. Gu G, Hentunen TA, Nars M et al. Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis 2005;10:583-595. Go to original source...
    25. Weinstein RS, Jilka RL, Parfitt AM et al. Inhibition of osteoblastogenesis and p motion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 1998;102:274-282. Go to original source...
    26. Kryštůfková O, Růžičková Š, Niederlová J, Vencovský J. Základní buněčné a mo­ lekulární principy remodelace kosti u revmatoidní artritidy. Čes Revmatol 2004;1:3-13.
    27. Holstead Jones D, Kong Y-Y. Penninger JM. Role of RANKL and RANK in bone loss and arthritis.Ann Rheum Dis 2002;61(Suppl II):ii32-ii39. Go to original source...
    28. Cooper MS. Sensitivity of bone to glucocorticoids. Clinical Science 2004;107: 111-123. Go to original source...
    29. Sivagurunathan S, Muir MM, Brenna TC, Seale JP, Mason RS. Influence of glu­ cocorticoids on human osteoclast generation and activity. J Bone Miner Res 2005; 20:390-398. Go to original source...
    30. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endo­ crinology. doi:10.1210/en.2006-0459.
    31. Colette C, Monnier L, Pares Herbute N, Blotman F and Mirouye J. Calcium ab­ sorption in corticoid treated subject - effects of a single oral dose of calcitriol. Horm Metab Res1987;19:335-338. Go to original source...
    32. Klen RG, Arnaud SB, Gallagher JC, Deluca HF and Riggs BL. Intestinal calcium absorption in exogenous hypercortisonizm. Role of 25-hydroxyvitamin D and cortisteroid dose. J Clin Invest 1977;60:253-259. Go to original source...
    33. Reid IR. Glucocorticoid osteoporosis-mechanism and management. Eur J Endo­ crinol 1977;137:209-217. Go to original source...
    34. Feher JJ, Wasserman RH. Intestinal calcium-binding protein and calcium absorp­ tion in cortisol-treated chicks: Effects of vitamin D3 and 1,25-dihydroxyvitamin D3. Endocrinology 1979;104:547-551. Go to original source...
    35. Kimberg DV, Baerg RD, Gershon E, Graudusius RT. Effect of cortisone treatment on the active transport of calcium by the small intestine. J clin Invest 1971;50: 1309-1321. Go to original source...
    36. Reid IR, Ibbertson HK. Evidence for decrease tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm Res 1987;27:200-204. Go to original source...
    37. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. 1975; J Clin Endocrinol Metab 40:774-779. Go to original source...
    38. MacAdams MR,White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986/1047639-648. Go to original source...
    39. Ptschan D, Loddenkemper K, Buttgereit F. Molecular mechanism of glucocorti­ coid-induced osteoporosis. Bone 2001;29:498-505. Go to original source...
    40. Schakman O,Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myo­ pathy. J Endocrinol 2008. In press. Go to original source...
    41. Bland R. Steroid hormone receptor expression and action in bone. Clinical Scien­ ce 2000;98:217-240. Go to original source...
    42. van Rossum EFC and Lamberts STJ. Polymorphism in the glucocorticoid recep­ tor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 2004;59:333-57. Go to original source...
    43. Canalis E. Mechanizm of glucocortiocoid-induced osteoporosis. Current Opinion in Rheumatology 2003;15:454-457. Go to original source...
    44. Takahashi M, Saha PK, Wehrli FW. Skeletal effects of short-term exposure to de­ xamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy. J Bone Miner Metab 2006;24:467-475. Go to original source...
    45. Saag KG, Shane ES, Boonen S et al. Teriparatide or alendronate in glucocortico­ id-induced osteoporosis. N Engl J Med 2007;357:2028-39. Go to original source...
    46. Růžičková O, Bayer M, Pavelka K, Ihlička V. Doporučení pro prevenci a léčbu glukokortikoidy indukované osteoporózy u pacientů s revmatickým onemocně­ ním. Čes Revmatol 2004;4:163-174.
    47. Homik J, Suarey-Almayor M, Shea B, Cranney et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;2: CD000952. Go to original source...
    48. de Nijs RNJ, Jacobs JWG, Algra A, Lems WF, Bijlsma JWJ. Prevention and tre­ atment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ trans­ plantation studies. Osteoporos Int 2004;15:589-602. Go to original source...
    49. Cranney A, Welch V, Adachi J, Homik J, Shea B et al. Calcitonin for the t and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;2:CD001983. Go to original source...
    50. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and tr ment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporo­ sis intervention study group. N Engl J Med 1998;339:292-299. Go to original source...
    51. Adachi JD Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoi domized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-211. Go to original source...
    52. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone den­ sity and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue 2000;67:277-285. Go to original source...
    53. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res 15:1006-1013. Go to original source...
    54. American College of Rheumatology Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update. American College of Rheumatology Ad Hoc Committee on Glucocortioid-induced osteoporosis. 2001;44:1496-1503.
    55. Guidelines working group for the Bone and Tooth Society, National Osteop Society and Royal College of Physicians Glucocorticoid-induced osteoporosis: guidelin don, UK.
    56. van Staa TP, Geusens P, Pols HAP et al. A simple score for estima term risk of fracture in patients using oral glucocorticoids. Q J Med 2005;98:191-198. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.